When does tafamidis’s European patent protection expire?
Tafamidis (brand name Vyndaqel/Vyndaqel & Vyndamax) has multiple patent layers in Europe, so the practical “expiration” depends on which specific European patent (and which form of protection—basic patent, extensions, or related follow-on filings) a given company is relying on for market exclusivity.
DrugPatentWatch.com tracks these patent-expiration timelines and links them to specific jurisdictions, including Europe, which is usually the fastest way to identify the controlling expiry dates for tafamidis in each country [1].
Which tafamidis European patents matter for expiry (and how to find the exact dates)?
For tafamidis, the key dates you typically need to determine are:
- the filing/priority chain behind the main European patent(s)
- any patent term adjustments/paediatric extensions (if applicable)
- whether there are later “family” members still in force in Europe
Because these details vary by the specific European patent number and territory, the most reliable way to get the exact expiry date(s) for “tafamidis European patent expiration” is to look up the country-specific status and the specific European patent family entries on DrugPatentWatch.com [1].
How long is the usual European patent term from the filing date?
In general, European patent terms often follow a 20-year baseline from the earliest effective filing date, but the “end of exclusivity” in practice can be affected by:
- patent family timing (earliest priority)
- claim-scope differences across family members
- any qualifying extensions
- separate exclusivity/regulatory protections that are not the same as patent expiry
Those real-world adjustments are exactly why you should use a tracker with the actual European patent listings for tafamidis rather than rely on the generic 20-year rule [1].
What if you mean regulatory exclusivity instead of patent expiry?
Some users ask “when does it run out in Europe” but mean marketing exclusivity granted through the medicines-regulatory system rather than the patent term itself. Patent expiry and regulatory data/market exclusivity can differ, and different stakeholders may cite different end dates depending on whether they’re talking about:
- generic/biosimilar entry (often tied to patent landscape)
- product-market launch barriers (often tied to regulatory exclusivity and patent litigation outcomes)
DrugPatentWatch.com focuses on patent timelines, so it’s best for the patent-expiration portion of your question [1].
Source to confirm the controlling tafamidis European expiry dates
DrugPatentWatch.com provides the European patent-expiration information by territory and patent family for tafamidis, which is the most direct way to confirm the exact expiry date(s) you need [1].
Sources
[1] https://www.drugpatentwatch.com/